Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis
Rodriguez E, Pei G, Zhao Z, Kim S, German A, Robinson P. Substance P Antagonism as a Novel Therapeutic Option to Enhance Efficacy of Cisplatin in Triple Negative Breast Cancer and Protect PC12 Cells against Cisplatin-Induced Oxidative Stress and Apoptosis. Cancers 2021, 13: 3871. PMID: 34359773, PMCID: PMC8345440, DOI: 10.3390/cancers13153871.Peer-Reviewed Original ResearchTriple-negative breast cancerSP-receptor antagonismTriple-negative breast cancer cell linesTherapeutic optionsBreast cancerSP receptorsCell linesFlow cytometryTriple negative breast cancerCisplatin-induced oxidative stressTriple-negative breast cancer cellsSubstance P antagonismEfficacy of cisplatinGenes associated with metastasisNegative breast cancerHigh-affinity SP receptorResponse to cisplatinCisplatin-inducedNeuronal cell lineTreatment strategiesProduction of reactive oxygen speciesCisplatinPC12 cellsCell cycle progressionReactive oxygen species